NCT07076758

Brief Summary

This study aims to investigate the correlation between serum copper levels and cardiac enzymes in patients with acute myocardial infarction (AMI).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 8, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2025

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

July 12, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 22, 2025

Completed
Last Updated

July 22, 2025

Status Verified

July 1, 2025

Enrollment Period

6 months

First QC Date

July 12, 2025

Last Update Submit

July 12, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Serum copper level

    Serum copper level will be recorded.

    Immediately after echocardiography (Up to 1 hour)

Secondary Outcomes (4)

  • Correlation between copper zinc and cardiac enzyme

    Immediately after echocardiography (Up to 1 hour)

  • Creatine kinase

    Immediately after echocardiography (Up to 1 hour)

  • MB fraction of creatine kinase

    Immediately after echocardiography (Up to 1 hour)

  • Cardiac troponin T

    Immediately after echocardiography (Up to 1 hour)

Study Arms (2)

Group I

Patients with acute myocardial infarction.

Other: Transthoracic echocardiography

Group II

Healthy control individuals as a control group.

Other: Transthoracic echocardiography

Interventions

Transthoracic echocardiography will be done for all patients during their cardiac care unit stay including two-dimensional and color Doppler echocardiography studies. It will be performed in the left lateral position using the parasternal and apical transducer positions. All studies will be technically adequate for scoring endocardial regional wall motion. The following views will be obtained: long-axis parasternal, short-axis parasternal, apical four chamber, apical two-chamber and apical five-chamber views. All the measurements taken will be according to the criteria of the American Society of Echocardiography

Group IGroup II

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This case-control study will be conducted at Sohag University Hospitals after approval from the institutional ethical committee.

You may qualify if:

  • Age ≥18 years old.
  • Both sexes.
  • Patients with acute myocardial infarction (AMI). AMI are defined as patients complaining of typical continuous chest pain for more than 30 min: ST-segment elevation of more than 0.1 mV in two or more successive leads or ST-segment depression of more than 0.1 mV in two or more successive leads monitored by a standard 12-lead ECG and rise of either creatine kinase (CK) or MB fraction of creatine kinase (CKMB) to greater than twice the normal level or elevation of troponin I \[cardiac troponin T (cTnT)\] more than or equal to 0.1 ng/ml

You may not qualify if:

  • Patients with insufficient clinical information.
  • Passed time MI (if patients presented with symptoms that lasted \>24 h).
  • Cardiogenic shock.
  • Chronic kidney disease.
  • Chronic liver cell failure.
  • Significant valvular heart disease.
  • Hematological disease.
  • Malignancy.
  • Severe liver or renal disease.
  • Systemic inflammatory disease.
  • Active infection.
  • Autoimmune disease.
  • Patients on steroids whatever the cause is.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, 82511, Egypt

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Cardiovascular, Faculty of Medicine, Sohag University, Sohag, Egypt.

Study Record Dates

First Submitted

July 12, 2025

First Posted

July 22, 2025

Study Start

January 1, 2025

Primary Completion

July 8, 2025

Study Completion

July 8, 2025

Last Updated

July 22, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations